Bone Marrow-Derived Multipotent Stromal Cells Attenuate Inflammation in Obliterative Airway Disease in Mouse Tracheal Allografts
Figure 4
MSCs inhibit T-cell response in the allografts. To assess T-cell response, grafts from each treatment group were explanted 4 weeks after transplantation; IV only (PBS, ; MSC, ), T (PBS, ; MSC, ), or IV + T group (PBS, ; MSC, ). (a)–(c) Tracheal sections stained with anti-CD3 antibodies (dark brown spots) showed significantly less numbers of infiltrated CD3-positive cells in the MSC/IV-treated group (a), MSC/T-treated group (b), and MSC/IV + T-treated group (c) at 4 weeks after transplantation when compared to the PBS-control group (all representative images 200x original magnification). (d) CD3-positive cells were counted in 4 random high power fields per section. Mean counts of cells 4 weeks after transplantation in each MSC treated group (IV only, T only, IV + T) were compared to the respective PBS-control group. Significantly fewer CD3-positive cells were seen in all MSC-treated groups at 4 weeks in IV group (), T group (), and IV + T group (). All error bars in (d) indicate SEM.
